• Search
  • Advanced Search
Tuberc Respir Dis > Volume 67(2); 2009 > Article
Original Article
Tuberculosis and Respiratory Diseases 2009;67(2):121-126.
DOI: https://doi.org/10.4046/trd.2009.67.2.121    Published online August 1, 2009.
Efficacy and Safety of Pemetrexed in Advanced Non-Small Cell Lung Carcinoma.
Gyu Jin Lee, Mann Hong Jung, Tae Won Jang, Chul Ho Ok, Hyun Joo Jung
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. jangtw@ns.kosinmed.or.kr
Abstract
BACKGROUND
Pemetrexed has been prescribed newly as a second line chemotherapy in advanced non-small cell lung carcinoma (NSCLC). The aim of study was to determine the efficacy and toxicity of pemetrexed in advanced NSCLC. METHODS: Patients with histologically or cytologically confirmed NSCLC were evaluated from June 2006 to December 2008. The patients had relapsed or progressed after prior chemotherapy treatment. They were treated with intravenous pemetrexed 500 mg/m2 for 10 min on Day 1 of each 21-day cycle. RESULTS: A total of 89 patients were eligible for analysis. The response rate and disease control rate were 11% and 66%. Non-squamous cell carcinoma histology was significantly associated with a superior response rate (p=0.035) and disease control rate (p=0.009) than squamous cell carcinoma histology. The median survival time was 13 months and the median progression free survival time was 2.3 months. The median survival time of patients with ECOG PS 0~1 was 13.2 months, whereas median survival time was 11.6 months for patients with PS 2 (p=0.002). The median progression free survival time of patients with PS 0~1 were 3.8 months, but 2.1 months for patients with PS 2 (p=0.016). The median progression free survival time of smokers with non-squamous cell carcinoma was 3.4 months, which was significant (p=0.014). Grade 3~4 neutropenia were seen in 7.9% patients. CONCLUSION: Pemetrexed has efficacy in patients who had prior chemotherapy with advanced NSCLC and less hematologic toxicity.
Key Words: Pemetrexed, Non-small-cell lung carcinoma, Drug therapy
TOOLS
METRICS Graph View
  • 0 Crossref
  • 1 Scopus
  • 3,343 View
  • 14 Download
Related articles

Combination Chemotherapy with Cisplatin and Etoposide in Non-Small Cell Lung Carcinoma1990 December;37(4)

p53 Expression Patterns in Non-small Cell Lung Cancers1993 December;40(6)

Clinical Study of Bronchioloalveolar Cell Carcinoma.1994 February;41(1)

Comparison of Single vs Combined Modality Treatment inLocally Advanced Non-Small Cell Lung Cancer.1995 August;42(4)

A Case of Amylase Producing Small Cell Lung Cancer.1997 June;44(3)

ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next